Skip to content

Robotic nephrectomy with oxycodone anesthesia throughout the surgery process: feasibility and perioperative functional outcomes

Robotic nephrectomy with oxycodone anesthesia throughout the surgery process: feasibility and perioperative functional outcomes

Status
Recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR-OOC-17011084
Enrollment
Unknown
Registered
2017-04-07
Start date
2017-04-15
Completion date
Unknown
Last updated
2017-04-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

the patient of robotic nephrectomy

Interventions

Treatment group:The use of oxycodone

Sponsors

Sir Run Run Shaw hospital,shool of medicine,zhejiang university
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 70 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria is for reference, and it can be adjusted according to the clinical experience. 1. Patients aged from 18 to 70 years; 2. Patients with nephrectomy surgery; 3. Patients with no other potential disease; 4. The ASA physical grade is I-II; 5. BMI 20 to 25; 6. Patiens with assigned written consent.

Exclusion criteria

Exclusion criteria: Exclusion criteria is for reference, and it can be adjusted according to the clinical experience. 1. Patients allergic to any anesthetic; 2. Patients with the history of heart surgery or cardiac insufficiency; 3. Patients with airway problems; 1) Patients with respiratory depression or anoxia; 2) Patients with COPD; 3) Patients with asthma or other bronchial disease; 4. Patients with hepatic disease or hepatic insufficiency; 1) The serum level of aspartate transaminase, alanine aminotransferase or alkaline phosphatase is increased more than 1.5 times of upper normal limits; 2) The serum level of bilirubin or creatinine is increased more than 1.5 times of upper normal limits; 3) The serum level of gamma-glutamyl transpeptidase is increased more than 1.5 times of upper normal limits; 5. Patients with renal insufficiency; 1) eGFR<90 mL/min/1.73 m2; 2) The creatinine clearance rate is out of the range of 80-125ml/min; 6. The taboo pointed out in the instructions for oxycodone; 7. Patients with uncontrolled muscle tension or seizure; 8. Patients with long-term use of analgetic or drug dependence; 9. Patients with intracranial hypertension; 10. Patients with cognition or communication impairment; 11. Pregnant or lactating patients; 12. Patients don't fit for oxycodone thought by other doctors; 13. Patiens without assigned written consent.

Design outcomes

Primary

MeasureTime frame
hemodynamic change (SBP, DBP, AMP, HR, RR, O2 Sat);

Secondary

MeasureTime frame
Bucking times during anesthesia induction;Bucking times during the whole surgery process;Body move times during the whole surgery process;Sensory and motor nerve block onset time and duration(Anesthesia time);The operation time;Pneumoperitoneum time;Wake-up time;Wake-up time;BIS;Muscle reaction/stabilization rating;NRS;FAS;NVAS;Oxycodone metabolites detection;Treatment satisfaction;Total drug use (propofol, oxycodone and so on);hospital stays and hospitalization expenses;QoR-40;

Countries

China

Contacts

Public ContactHaihong Wang

Zhejiang University

wanghaihong@zju.edu.cn+86 13857105704

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026